Karin Heidemann
Chief Tech/Sci/R&D Officer chez CHAMPIONS ONCOLOGY, INC.
Profil
Karin Abarca Heidemann is currently the Executive Vice President-Scientific Operations at Champions Oncology, Inc. Previously, she worked as the Vice President-Scientific Operations at Rockland Immunochemicals, Inc. from 2011 to 2019.
She completed her undergraduate degree at Universität zu Köln.
Postes actifs de Karin Heidemann
| Sociétés | Poste | Début |
|---|---|---|
| CHAMPIONS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01/09/2019 |
Anciens postes connus de Karin Heidemann
| Sociétés | Poste | Fin |
|---|---|---|
Rockland Immunochemicals, Inc.
 Rockland Immunochemicals, Inc. BiotechnologyHealth Technology Rockland Immunochemicals, Inc. is a biotech company that was founded in 1962. The private company is based in Limerick, PA and has subsidiaries in the United States and Germany. The company specializes in manufacturing cutting-edge tools for basic, applied, and clinical research. The company offers custom anti-id antibodies for specific therapeutic development and tissue powders that can be used as a specific adsorbent to remove unwanted reactivities or as source material. The CEO of Rockland Immunochemicals is James Fendrick. | Corporate Officer/Principal | 01/09/2019 |
Formation de Karin Heidemann
| Universität zu Köln | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHAMPIONS ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Rockland Immunochemicals, Inc.
Rockland Immunochemicals, Inc. BiotechnologyHealth Technology Rockland Immunochemicals, Inc. is a biotech company that was founded in 1962. The private company is based in Limerick, PA and has subsidiaries in the United States and Germany. The company specializes in manufacturing cutting-edge tools for basic, applied, and clinical research. The company offers custom anti-id antibodies for specific therapeutic development and tissue powders that can be used as a specific adsorbent to remove unwanted reactivities or as source material. The CEO of Rockland Immunochemicals is James Fendrick. | Health Technology |
